ABCL

ABCL

USD

AbCellera Biologics Inc. Common Shares

$3.150-0.050 (-1.563%)

リアルタイム価格

Healthcare
バイオテクノロジー
カナダ

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$3.200

高値

$3.310

安値

$3.080

出来高

8.00M

企業ファンダメンタルズ

時価総額

940.2M

業種

バイオテクノロジー

Canada

取引統計

平均出来高

4.49M

取引所

NMS

通貨

USD

52週レンジ

安値 $1.891現在値 $3.150高値 $3.68

関連ニュース

Analyst Upgrades

Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10

Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics with a Buy and lowers the price target from $28 to $10.

もっと見る
Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10
BusinessWire

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial

もっと見る
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
BusinessWire

AbCellera Reports Q1 2025 Business Results

AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a

もっと見る
AbCellera Reports Q1 2025 Business Results
BusinessWire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies AbCellera (NASDAQ:ABCL) today announced new

もっと見る
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025